ERBB2 and breast carcinoma: Finally, LBx-based HER2 amplification detection in advanced breast cancer patients is challenged by the fact that the primary tissue status may not necessarily reflect that of metastatic disease throughout the body, leading to tissue-plasma discordance [62].